Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
J Clin Immunol ; 40(6): 861-871, 2020 08.
Artículo en Inglés | MEDLINE | ID: mdl-32602054

RESUMEN

Nijmegen breakage syndrome (NBS) is a DNA repair disorder characterized by combined immunodeficiency and a high predisposition to malignancies. HSCT appears to cure immunodeficiency, but remains challenging due to limited experience in long-term risks of transplant-associated toxicity and malignancies. Twenty NBS patients received 22 allogeneic HSCTs with TCRαß/CD19+ graft depletion with fludarabine 150 mg/m2, cyclophosphamide 20-40 mg/kg and thymoglobulin 5 mg/kg based conditioning regimens (CRs). Twelve patients additionally received low-dose busulfan 4 mg/kg (Bu group) and 10 patients (including 2 recipients of a second HSCT) treosulfan (Treo group) 30 g/m2. Overall and event-free survival were 0.75 vs 1 (p = 0.16) and 0.47 vs 0.89 (p = 0.1) in the Bu and Treo groups, respectively. In the Bu group, four patients developed graft rejection, and three died: two died of de novo and relapsed lymphomas and one died of adenoviral hepatitis. The four living patients exhibited split chimerism with predominantly recipient myeloid cells and predominantly donor T and B lymphocytes. In Treo group, one patient developed rhabdomyosarcoma. There was no difference in the incidence of GVHD, viral reactivation, or early toxicity between either group. Low-dose Bu-containing CR in NBS leads to increased graft failure and low donor myeloid chimerism. Treo-CR followed by TCRαß/CD19-depleted HSCT demonstrates a low level of early transplant-associated toxicity and enhanced graft function with stable donor chimerism.


Asunto(s)
Busulfano/análogos & derivados , Trasplante de Células Madre Hematopoyéticas/métodos , Depleción Linfocítica , Agonistas Mieloablativos/uso terapéutico , Síndrome de Nijmegen/terapia , Acondicionamiento Pretrasplante/métodos , Antígenos CD19/metabolismo , Busulfano/administración & dosificación , Busulfano/efectos adversos , Busulfano/uso terapéutico , Femenino , Rechazo de Injerto , Supervivencia de Injerto/inmunología , Enfermedad Injerto contra Huésped/etiología , Enfermedad Injerto contra Huésped/prevención & control , Trasplante de Células Madre Hematopoyéticas/efectos adversos , Humanos , Inmunosupresores/administración & dosificación , Inmunosupresores/efectos adversos , Inmunosupresores/uso terapéutico , Depleción Linfocítica/métodos , Masculino , Agonistas Mieloablativos/administración & dosificación , Síndrome de Nijmegen/diagnóstico , Síndrome de Nijmegen/mortalidad , Cuidados Posoperatorios , Pronóstico , Receptores de Antígenos de Linfocitos T alfa-beta/metabolismo , Estudios Retrospectivos , Linfocitos T/inmunología , Linfocitos T/metabolismo , Quimera por Trasplante , Acondicionamiento Pretrasplante/efectos adversos , Resultado del Tratamiento
2.
Front Immunol ; 11: 602482, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-33488600

RESUMEN

Nijmegen breakage syndrome (NBS) is a DNA repair disorder characterized by combined immunodeficiency and a high predisposition to lymphoid malignancies. The majority of NBS patients are identified with a homozygous five base pair deletion in the Nibrin (NBN) gene (c.657_661del5, p.K219fsX19) with a founder effect observed in Caucasian European populations, especially of Slavic origin. We present here an analysis of a cohort of 136 NBS patients of Eastern Slav origin across Belarus, Ukraine, Russia, and Latvia with a focus on understanding the geographic distribution, incidence of malignancy, and treatment outcomes of this cohort. Our analysis shows that Belarus had the highest prevalence of NBS (2.3 per 1,000,000), followed by Ukraine (1.3 per 1,000,000), and Russia (0.7 per 1,000,000). Of note, the highest concentration of NBS cases was observed in the western regions of Belarus and Ukraine, where NBS prevalence exceeds 20 cases per 1,000,000 people, suggesting the presence of an "Eastern Slavic NBS hot spot." The median age at diagnosis of this cohort ranged from 4 to 5 years, and delay in diagnosis was more pervasive in smaller cities and rural regions. A total of 62 (45%) patients developed malignancies, more commonly in males than females (55.2 vs. 34.2%; p=0.017). In 27 patients, NBS was diagnosed following the onset of malignancies (mean age: 8 years). Malignancies were mostly of lymphoid origin and predominantly non-Hodgkin lymphoma (NHL) (n=42, 68%); 38% of patients had diffuse large B-cell lymphoma. The 20-year overall survival rate of patients with malignancy was 24%. However, females with cancer experienced poorer event-free survival rates than males (16.6% vs. 46.8%, p=0.036). Of 136 NBS patients, 13 underwent hematopoietic stem cell transplantation (HSCT) with an overall survival of 3.5 years following treatment (range: 1 to 14 years). Indications for HSCT included malignancy (n=7) and immunodeficiency (n=6). Overall, 9% of patients in this cohort reached adulthood. Adult survivors reported diminished quality of life with significant physical and cognitive impairments. Our study highlights the need to improve timely diagnosis and clinical management of NBS among Eastern Slavs. Genetic counseling and screening should be offered to individuals with a family history of NBS, especially in hot spot regions.


Asunto(s)
Proteínas de Ciclo Celular , Efecto Fundador , Neoplasias Hematológicas , Trastornos Linfoproliferativos , Síndrome de Nijmegen , Proteínas Nucleares , Adolescente , Adulto , Proteínas de Ciclo Celular/genética , Proteínas de Ciclo Celular/inmunología , Niño , Preescolar , Europa Oriental/epidemiología , Femenino , Estudios de Seguimiento , Neoplasias Hematológicas/genética , Neoplasias Hematológicas/inmunología , Neoplasias Hematológicas/mortalidad , Humanos , Incidencia , Trastornos Linfoproliferativos/genética , Trastornos Linfoproliferativos/inmunología , Trastornos Linfoproliferativos/mortalidad , Masculino , Síndrome de Nijmegen/genética , Síndrome de Nijmegen/inmunología , Síndrome de Nijmegen/mortalidad , Proteínas Nucleares/genética , Proteínas Nucleares/inmunología , Prevalencia , Calidad de Vida , Estudios Retrospectivos
3.
Pediatr Blood Cancer ; 57(1): 160-2, 2011 Jul 15.
Artículo en Inglés | MEDLINE | ID: mdl-21557461

RESUMEN

Central nervous system (CNS) involvement is an independent risk factor for poor event-free survival and relapse confined to the CNS. Knock-out mice deprived of RAG2, the protein involved in DNA repair, developed leukemic infiltration within leptomeninges. Therefore, we hypothesized that DNA repair deficiencies in humans, such as Nijmegen breakage syndrome (NBS), may constitute a risk factor for CNS dissemination of acute lymphoblastic leukemia (ALL). Having analyzed the incidence of CNS2/CNS3 status at diagnosis of ALL in two independent cohorts from the Polish Pediatric Leukemia/Lymphoma Study Group, we noticed that among children with NBS CNS involvement was significantly frequent.


Asunto(s)
Sistema Nervioso Central/patología , Infiltración Leucémica/mortalidad , Infiltración Leucémica/patología , Síndrome de Nijmegen/mortalidad , Síndrome de Nijmegen/patología , Leucemia-Linfoma Linfoblástico de Células Precursoras/mortalidad , Leucemia-Linfoma Linfoblástico de Células Precursoras/patología , Adolescente , Animales , Sistema Nervioso Central/metabolismo , Niño , Preescolar , Proteínas de Unión al ADN/genética , Proteínas de Unión al ADN/metabolismo , Supervivencia sin Enfermedad , Femenino , Humanos , Lactante , Infiltración Leucémica/tratamiento farmacológico , Infiltración Leucémica/metabolismo , Masculino , Ratones , Ratones Noqueados , Síndrome de Nijmegen/tratamiento farmacológico , Síndrome de Nijmegen/genética , Proteínas Nucleares/genética , Proteínas Nucleares/metabolismo , Leucemia-Linfoma Linfoblástico de Células Precursoras/tratamiento farmacológico , Leucemia-Linfoma Linfoblástico de Células Precursoras/metabolismo , Estudios Retrospectivos , Factores de Riesgo , Tasa de Supervivencia
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA